Genmab's experimental ADC rinatabart sesutecan posted a 45.9% response rate in platinum-resistant ovarian cancer, where standard chemo barely cracks 15%. The durability data might be even more impressive.
Platinum-resistant ovarian cancer is one of the cruelest diagnoses in oncology. Not because treatments don't exist, but because they barely work. Standard chemotherapy produces response rates of roughly 10% to 15%, and those responses tend to vanish within a few months. It's the medical equivalent of bailing water out of a sinking boat with a coffee mug.
So when Genmab dropped new data showing its experimental drug, rinatabart sesutecan, produced responses in nearly half of patients and kept many of them responding for over a year? That's not a coffee mug. That might be a pump.
The Numbers That Matter
Genmab's Phase 1/2 trial, called RAINFOL-01 Part C, enrolled 109 patients with platinum-resistant ovarian cancer who had already been through one to three rounds of prior treatment. These are patients who've already seen their options dwindle.
The confirmed objective response rate (basically, the percentage of patients whose tumors shrank meaningfully) came in at 45.9%. Five patients achieved complete responses, meaning their tumors disappeared entirely on scans. Compare that to the 10–15% response rate you'd expect from standard single-agent chemo, and you start to see why oncologists are paying attention.
But response rate alone doesn't tell the whole story. The real question in platinum-resistant ovarian cancer is always: how long does it last? Tumors in this setting have a nasty habit of bouncing back fast. The median duration of response here was 12.1 months, and 51% of responders were still responding at the one-year mark. Median progression-free survival clocked in at 9.5 months. For a population where a few months of benefit is the norm, that kind of durability is genuinely striking.
How the Drug Actually Works
Rinatabart sesutecan (sometimes shortened to Rina-S, because pharma loves abbreviations) is an antibody-drug conjugate, or ADC. Think of an ADC as a guided missile: the antibody is the GPS system that finds the tumor, and the payload is the warhead that destroys it.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
In this case, the antibody locks onto a protein called folate receptor alpha (FRα), which sits on the surface of many ovarian cancer cells. Once it binds, the whole package gets pulled inside the cell, where a specially designed linker breaks apart and releases the toxic payload: exatecan, a drug that damages DNA by blocking an enzyme called topoisomerase I. The cancer cell can't repair the damage. It dies.
What makes Rina-S interesting from an engineering standpoint is its homogeneous drug-to-antibody ratio of 8. Translation: each antibody missile carries roughly twice the payload of many competing ADCs. More warheads per missile, in theory, means more killing power per delivery.
The Safety Story Looks Clean (So Far)
Potent cancer-killing drugs usually come with a catch: brutal side effects. But Genmab's data showed a surprisingly tidy safety profile. Only 5.5% of patients discontinued treatment due to adverse events, which is low for this drug class. And several of the scariest ADC side effects, including eye toxicity, lung inflammation (interstitial lung disease), nerve damage, and severe mouth sores, were notably absent.
That's a meaningful differentiator. Some competing ADCs have been plagued by these exact problems, forcing dose reductions or treatment stops. If Rina-S can maintain this tolerability in larger trials, it becomes a much easier sell to both doctors and regulators.
A Crowded Dance Floor
Rina-S isn't waltzing into an empty ballroom. The ovarian cancer ADC landscape has gotten competitive fast.
The current king of the hill is mirvetuximab soravtansine (Elahere), the first FDA-approved ADC for ovarian cancer, also targeting FRα. It carved out a niche in FRα-high platinum-resistant disease and has become a guideline-recommended option. Any new FRα-targeted ADC has to beat, or at least match, mirvetuximab's profile to matter.
Behind mirvetuximab, there's a whole pack of next-generation FRα ADCs reporting single-agent response rates in the 31% to 56% range. Companies are also chasing different targets entirely, including HER2, TROP2, B7-H4, and mesothelin, hoping to reach patients whose tumors don't express enough FRα to qualify for that class of drugs.
AbbVie recently showed early Phase 1 data for its c-Met-targeting ADC in platinum-resistant ovarian cancer, adding yet another angle of competition. The field is moving from "do we have any good options?" to "which of these many options is best for which patient?" That's a good problem to have.
Why Genmab Needs This Win
Genmab isn't just running a clinical trial; it's building an empire. The company recently completed its $8 billion acquisition of Merus, snagging petosemtamab, a late-stage bispecific antibody for head-and-neck cancer. The stated goal is a standalone oncology franchise built on three pillars: petosemtamab, Rina-S, and its existing drug EPKINLY, with multiple new launches targeted by 2027.
That's an ambitious timeline. And it means Rina-S isn't just a nice pipeline asset; it's one of the load-bearing walls of Genmab's entire corporate strategy. Strong data in ovarian cancer validates not only the drug but the broader ADC platform technology behind it.
Wall Street seems cautiously optimistic. The combination of strong efficacy, durable responses, and a clean safety profile in a notoriously difficult cancer gives analysts plenty to like. Some commentators have also noted Genmab's ongoing combination studies pairing Rina-S with bevacizumab, which could further expand the drug's commercial potential.
What Comes Next
These are still Phase 1/2 results in 109 patients. Impressive, yes. But the road from mid-stage data to FDA approval is littered with drugs that looked great in small trials and stumbled in larger ones. Genmab will need a registrational study (a larger, more definitive trial designed to support approval) to get Rina-S across the finish line.
The question isn't whether this drug works. The early data suggests it does. The question is whether it works well enough, safely enough, and in enough patients to carve out real market share against an increasingly crowded field of competitors.
For the thousands of women diagnosed with platinum-resistant ovarian cancer each year, though, the growing competition is the best possible news. After decades of incremental progress and disappointing response rates, they're finally getting options that might actually change the trajectory of their disease. And that coffee mug? It's starting to look a lot more like a pump.
6 min read
The FDA Just Declared a Space Race Against China
The FDA just built an entirely new office because China's drug development machine is catching up. The agency is speeding up domestic trials while tightening scrutiny on foreign data, and the competitive implications for U.S. biotech are massive.
